None · None

Madrigal Pharmaceuticals, Inc. MDGL

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Company profile

Business mix

  • It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
  • Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters

Current firm holders

Firm Weight Value Filing period
Baker Bros. Advisors 6.4% $1.1B 2026-03-31

Recent trading changes over the last 4 quarters

Net buyers 1 Last 4 13F filing periods
Net reducers 1 Last 4 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $87.5M Estimated from net added shares
Reduction amount $20.9M Estimated from net reduced shares
Net share change / base shares +6.1% +127,111 / 2,094,590
Alkeon Capital Management 2 filing periods
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 100.0% 13F value change +$84.7M
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -66.7% 13F value change -$97.9M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 120,000 Last 4 periods -40,000 (-33.3%) Total shares 80,000 Value $41.9M
Baker Bros. Advisors 4 filing periods
13F 2025-06-30 Filed 2025-08-14
Minor increase Shares 0.1% 13F value change -$56.0M
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 8.4% 13F value change +$384.3M
13F 2025-12-31 Filed 2026-02-17
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-15
Unchanged Shares 0.0% 13F value change $0
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 1,974,590 Last 4 periods +167,111 (+8.5%) Total shares 2,141,701 Value $1.1B

Recent mentions

No public mentions.